Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2013

View Archived Issues

p16INK4A-luciferase model monitors neoplastic transformation and senescence

Sanofi reviews accomplishments of 2012

Repros Therapeutics provides update on two core clinical programs

Further preclinical work supports potential use of ISCO's hpSC-derived hepatocytes

Researchers at Actelion Pharmaceuticals present novel P2X7 receptor antagonists

Infinity Pharmaceuticals and Intellikine patent new PI3K inhibitors

ImmunoGen achieves patient enrollment milestone in phase II NORTH trial

Lycera enters into new collaboration with Merck & Co.

NIAID grant awarded to study solithromycin in cystic fibrosis

Plans for new study of OGX-427 in bladder cancer announced

RQx Pharmaceuticals and Genentech form drug discovery collaboration

Phase III palifosfamide trial reaches target for progression-free survival events

European venous thromboembolism registry commences enrollment

Merck & Co. discloses new tyrosine-protein kinase inhibitors

AbbVie synthesizes new WEE1 inhibitors

GlaxoSmithKline patents novel Lp-PLA2 inhibitors

Thioridazine differentiates transformed embryonic stem cells

Sanofi synthesizes novel cathepsin A inhibitors

Gilead Sciences updates progress of fourth quarter 2012

New radiodiagnostic agents divulged by GE Healthcare

MorphoSys and Heptares enter GPCR antibody agreement

FDA clears phase IIa trial of fingolimod in ALS

Ongoing desmoteplase trials described at International Stroke Conference

FDA grants breakthrough therapy designations to ibrutinib for two B-cell malignancies

FDA advisory committee votes in favor of BLA for botulism antitoxin product